GET DAILY SIGNALSWhy Is Jaguar Health (JAGX) Stock Up +822.85% Today?
Key Takeaways
- Shares surged roughly 822.85% on September 22, 2026, climbing from a prior close of $2.67 to around $24.64.
- Primary catalyst: The U.S. Food and Drug Administration (FDA) granted a Prescription Drug User Fee Act (PDUFA) fee waiver for the company's lead drug, Mytesi, for fiscal year 2027.
- Amplifying factor: An extremely low float — roughly 344,553 shares outstanding after a 1-for-15 reverse split — made the stock highly susceptible to outsized, momentum-driven moves.
- Mechanics of the move: The rally exhibited hallmarks of a short squeeze and low-float momentum trading, punctuated by exchange volatility pauses.
- What to watch next: Earnings expected around November 12, 2026, and progress toward a crofelemer New Drug Application targeted for mid-2027.
Opening Summary
Jaguar Health, Inc. (JAGX), a San Francisco-based commercial-stage pharmaceutical company that develops plant-derived prescription medicines for gastrointestinal disorders, staged one of the most dramatic single-session rallies of the year. The stock exploded higher by approximately +822.85%, rising from a prior-session close of $2.67 to roughly $24.64 in intraday trading on September 22, 2026.
The immediate trigger cited by markets was a regulatory reprieve: the FDA granted the company's Napo Pharmaceuticals unit a waiver of the PDUFA fee associated with Mytesi (crofelemer delayed-release tablets) for fiscal year 2027. Combined with a severely constrained share count following a recent reverse stock split, the news ignited an aggressive, volatility-driven buying surge.
FDA Fee Waiver Ignites the Rally
The headline catalyst was regulatory rather than a fundamental earnings event. Jaguar Health announced that its family company, Napo Pharmaceuticals, received an FDA waiver of the fee tied to the Prescription Drug User Fee Act for Mytesi, an FDA-approved prescription treatment for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi is currently commercialized in the United States by Future Pak, LLC.
In isolation, a fee waiver represents a modest cost-saving development rather than a transformative commercial milestone. However, for a micro-cap company with persistent operating losses and a tightly constrained share count, even incremental positive news can act as a powerful catalyst. The announcement gave momentum traders and short sellers alike a concrete reason to reassess the stock, and the result was a violent re-pricing to the upside.
Reverse Split and Low Float Amplify the Move
The extraordinary magnitude of the gain cannot be understood without the company's recent capital-structure changes. On September 17, 2026, JAGX completed a 1-for-15 reverse stock split, executed to support compliance with Nasdaq's minimum bid price listing standards. The split reduced the number of outstanding common shares to roughly 344,553 — an exceptionally small float for a publicly traded company.
That low float made the stock unusually sensitive to shifts in supply and demand. When the FDA waiver news broke, a rush of buyers chased a limited pool of tradable shares, producing a short squeeze-like dynamic that sent the price sharply higher and triggered multiple volatility halts throughout the session. Such moves are characteristic of heavily traded micro-cap names where short interest and retail momentum converge.
Market Context and Trading Activity
Trading activity was intense, with volume running well above the stock's recent averages as the squeeze unfolded. The move was idiosyncratic rather than a reflection of broader market conditions: the biotechnology and healthcare sectors showed no comparable rally, and the surge was driven almost entirely by company-specific news and the stock's unique float dynamics.
From a technical standpoint, the stock tore through every near-term resistance level and left its recent trading range far behind. After spending the days following the reverse split near the $2.50–$2.90 level, JAGX broke decisively higher, with exchange-imposed volatility pauses underscoring the speed and force of the move. Traders should note that such parabolic, low-float rallies are often accompanied by sharp reversals as momentum fades.
What Comes Next for JAGX
Investors will now watch whether the company can convert today's regulatory win into sustained progress. The company has targeted an NDA submission for crofelemer in microvillus inclusion disease (MVID) — a rare and severe pediatric gastrointestinal disorder — by mid-2027, following the recent milestone in which all randomized pediatric patients advanced to a single-blind extension phase of a pivotal trial.
Key dates include the company's next quarterly earnings report, expected around November 12, 2026, as well as any updates on business development discussions for its intestinal failure program. Risks remain substantial: the company continues to report net losses, carries limited cash resources, and has relied on repeated reverse splits to maintain its Nasdaq listing. The same low float that fueled today's rally can work just as forcefully in reverse if sentiment cools.
Trending AI Robots
For traders seeking a systematic edge in fast-moving markets, Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, yet only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving investors a range of data-driven approaches. Explore the Trending AI Robots page to see which strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for JAGX turns negative, indicating new downward trend
JAGX saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 67 similar instances where the indicator turned negative. In 65 of the 67 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for JAGX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for JAGX just turned positive on October 26, 2026. Looking at past instances where JAGX's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +10.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAGX advanced for three days, in 138 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
JAGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.070) is normal, around the industry mean (3.104). P/E Ratio (0.001) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.003) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. JAGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals
Industry Biotechnology
Advertisement